Related Experiment Videos

Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray

Kazuhiro Suganuma1, Tetsuro Kubota, Yoshiro Saikawa

  • 1Department of Surgery, School of Medicine, Keio University, Sinjuku-ku, Tokyo 160-8582, Japan. tkubota@sc.itc.keio.ac.jp

Cancer Science
|June 26, 2003
PubMed

Insights

This study used microarray technology to identify genes linked to gastric cancer chemoresistance, discovering potential biomarkers like HB-EGF for cisplatin and 5-FU resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gastric cancer exhibits significant chemoresistance, necessitating identification of related genes.
  • Understanding chemoresistance mechanisms is crucial for improving treatment efficacy.

Purpose of the Study:

  • To identify genes associated with chemoresistance in gastric cancer using cDNA microarray.
  • To evaluate gene expression patterns in relation to sensitivity and resistance to common chemotherapeutic agents.

Main Methods:

  • Oligonucleotide microarray analysis of 6300 genes in 35 gastric cancer specimens.
  • Chemoresistance determination using MTT assay for cisplatin (DDP), 5-fluorouracil (5-FU), mitomycin C, and doxorubicin.
  • Gene expression analysis and selection based on differential expression in resistant versus sensitive tumors and normal mucosa.

Main Results:

  • Identified 23 candidate DDP-resistance-related genes, including vascular permeability factor and retinoblastoma-binding protein-1.
  • Metallothionein-IG and heparin-binding epidermal growth factor-like growth factor (HB-EGF) were selected as candidate DDP-resistance genes.
  • Glutathione-S-transferase and cyclooxygenase-2 families, dihydropyrimidine dehydrogenase, and HB-EGF were implicated in DDP and 5-FU resistance.

Conclusions:

  • Oligonucleotide microarrays are effective for identifying chemoresistance factors in gastric cancer.
  • Specific genes like HB-EGF show potential as biomarkers for predicting response to chemotherapy.
  • Further validation of identified genes is warranted for clinical application.

Related Concept Videos